• Becton, Dickinson and Company reported its third-quarter fiscal 2026 results, with sales rising to US$4,983 million while quarterly and year-to-date net income fell compared with the prior year, and it updated full-year 2026 guidance to expect low single-digit plus GAAP revenue growth.
• This was the first full quarter after spinning off its biosciences and diagnostics business, highlighting a more focused medical technology portfolio and new drug-delivery collaborations such as the semaglutide pen launch with EMS in Brazil.
• We’ll now examine how BD’s stronger-than-expected quarter and raised full-year guidance could influence its existing investment narrative.

We've uncovered the 8 dividend fortresses yielding 5%+ that don't just survive market storms, but thrive in them.

Becton Dickinson Investment Narrative Recap

To own Becton Dickinson, you need to believe in a focused medical technology company that can turn a consumables-heavy portfolio and operational discipline into steadier earnings. The third-quarter revenue increase and raised full-year outlook support the near term catalyst of margin and cash flow improvement, but the drop in net income and ongoing one off items keep execution risk around the recent spin off and cost structure very much in view.

The new collaboration with EMS on a semaglutide pen in Brazil ties directly into one of BD’s key catalysts: deeper exposure to injectable therapies for chronic diseases. It showcases how BD’s drug delivery platforms can participate in the growth of GLP 1 type treatments, but it also sits against risks around pricing pressure, regulatory scrutiny, and potential supply chain issues that could affect how far these opportunities translate into financial results.

Yet even with this upbeat quarter, investors should be aware that rising regulatory and cost containment pressures could still...

Becton Dickinson's narrative projects $21.4 billion revenue and $2.1 billion earnings by 2029. This implies revenues will decrease by 1.6% per year and requires an earnings increase of about $0.5 billion from $1.6 billion today.

Uncover how Becton Dickinson's forecasts yield a $189.58 fair value, a 5% upside to its current price.

Exploring Other Perspectives

Before this quarter, the most optimistic analysts were banking on earnings rising to about US$1.8 billion by 2029 and a richer PE of 37.6x, which is far more upbeat than consensus and assumes BD Excellence and digital initiatives offset the very funding and pricing pressures now in sharper focus after the latest results.

Explore 3 other fair value estimates on Becton Dickinson - why the stock might be worth as much as 29% more than the current price!

Reach Your Own Conclusion

Don't just follow the ticker - dig into the data and build a conviction that's truly your own.

• A great starting point for your Becton Dickinson research is our analysis highlighting 4 key rewards and 2 important warning signs that could impact your investment decision.
• Our free Becton Dickinson research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Becton Dickinson's overall financial health at a glance.

Searching For A Fresh Perspective?

Opportunities like this don't last. These are today's most promising picks. Check them out now:

• Invest in the nuclear renaissance through our list of 90 elite nuclear energy infrastructure plays powering the global AI revolution.
• Find 49 companies with promising cash flow potential yet trading below their fair value.
• The future of work is here. Discover the 39 top robotics and automation stocks leading the charge in AI-driven automation and industrial transformation.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.